Adding more lines of treatment may reduce the risk of rehospitalization among adults with PAH who are taking only one ...

The FDA has endorsed plans for a Phase 2b clinical trial that will test CS1, Cereno Scientific's experimental treatment for ...

Transplanting gut microbes from healthy rats into a rat model of PAH led to a reduction in disease severity, suggesting a ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

Low-dose metformin delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of PAH in rats.

The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of ...

Yutrepia's maker, Liquidia, has scheduled a first commercial shipment of the PH therapy to be available at specialty pharmacies.

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough device status to the Gradient Denervation System, an ultrasound-based catheter for treating pulmonary hypertension (PH). A ...